Peripheral vascular disease risk in diabetic individuals without coronary heart disease.
暂无分享,去创建一个
[1] J. Bosch,et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.
[2] Khalid Yusoff,et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.
[3] F. Kronenberg,et al. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. , 2017, The lancet. Diabetes & endocrinology.
[4] J. Berger,et al. Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. , 2017, Journal of the American College of Cardiology.
[5] L. Fleisher,et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.
[6] J. Berger,et al. Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease , 2017, American heart journal.
[7] R. Stein,et al. Association Between Physical Activity and Peripheral Artery Disease and Carotid Artery Stenosis in a Self-Referred Population of 3 Million Adults , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[8] Binita Shah,et al. Diabetes and Vascular Disease in Different Arterial Territories , 2014, Diabetes Care.
[9] Igor Rudan,et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis , 2013, The Lancet.
[10] J. Cooke,et al. Alternative ankle-brachial index method identifies additional at-risk individuals. , 2013, Journal of the American College of Cardiology.
[11] J. Saaddine,et al. Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.
[12] Yu Guo,et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. , 2013, Journal of the American College of Cardiology.
[13] M. M. Joosten,et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. , 2012, JAMA.
[14] G. Tomaselli,et al. Letter by Tomaselli and Holmes regarding article, "2011 ASA/ACCF/AHA/AANN/AANS/ACR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease". , 2012, Circulation.
[15] J. Shaw,et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.
[16] Gary Friday,et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. , 2011, Stroke.
[17] Deepak L. Bhatt,et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.
[18] M. Criqui,et al. Atherosclerotic Peripheral Vascular Disease Symposium II: screening for atherosclerotic vascular diseases: should nationwide programs be instituted? , 2008, Circulation.
[19] W. Katon,et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. , 2008, The American journal of managed care.
[20] T. Manolio,et al. Intrinsic contribution of gender and ethnicity to normal ankle-brachial index values: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2007, Journal of vascular surgery.
[21] Rodney A. White,et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography , 2006, Circulation.
[22] B. Howard,et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. , 2006, Diabetes care.
[23] Seppo Lehto,et al. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.
[24] H. Resnick,et al. Prevalence of elevated ankle-brachial index in the United States 1999 to 2002. , 2005, The American journal of medicine.
[25] Elizabeth Selvin,et al. Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999–2000 , 2004, Circulation.
[26] P. Sorlie,et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. , 2004, Diabetes care.
[27] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .
[28] K. Johansen,et al. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. , 2001, Journal of the American Society of Nephrology : JASN.
[29] S. Yusuf,et al. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.
[30] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[31] R. Holman,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.
[32] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[33] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[34] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[35] J. Shaw,et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. , 2011, Diabetes research and clinical practice.
[36] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .